PipelineReview. Business Intellegence Center

Proteins and Peptides

10 June 2016

Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar® Gel Trial in Lupus

7 June 2016

Merz Receives CE Mark for Radiesse® (+) Lidocaine

7 June 2016

Cristalia obtains registration for first biotechnological pharmaceutical ingredient

7 June 2016

Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity

7 June 2016

Neurovive Pharmaceutical: NeuroVive Announces CiPRICS Study Completes Enrolment

7 June 2016

New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen

6 June 2016

ARMO BioSciences’ AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoi

6 June 2016

Frontier Biotech’s Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

5 June 2016

Celldex Therapeutics’ CDX‑1401, CDX‑301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma

4 June 2016

Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20

3 June 2016

ADI-PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer

1 June 2016

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Leber’s Hereditary Optic Neuropathy

28 May 2016

Semaglutide Demonstrated Superior Glycemic Control vs Insulin Glargine U100 in Adults with Type 2 Diabetes

28 May 2016

Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

27 May 2016

SIPPET, an international randomized study, reports 87% higher incidence of inhibitors with recombinant factor VIII in patients with severe hemophilia A

27 May 2016

U.S. FDA Approves CSL Behring’s AFSTYLA® — The First and Only Recombinant Factor VIII Single Chain Therapy for Hemophilia A

27 May 2016

Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowel Syndrome

27 May 2016

FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes

25 May 2016

Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230

25 May 2016

Baxalta Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)

25 May 2016

IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee

24 May 2016

Allergan’s BOTOX Vista® (botulinum toxin type A) Receives National Marketing Authorisation in Japan for Treatment of Crow’s Feet Lines in Adult Patients

19 May 2016

Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study

19 May 2016

Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI

16 May 2016

Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of haemophilia B

14 May 2016

Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B

12 May 2016

European Commission Approves IDELVION® –CSL Behring’s Novel Hemophilia B Treatment with Up to 14-day Dosing Intervals

10 May 2016

Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery

9 May 2016

Avelas Biosciences Announces Positive Interim Phase 1b Results and Advances to Dose Expansion Stage

6 May 2016

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

SubscribeNewsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

SubscribeNewsletter new product alert

Featured reports

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis
Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective
Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review
Bispecific Antibodies for Immuno-Oncology & Other Diseases
Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
B7-H3-Targeted Immunotherapy Candidates Pipeline Review
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
Report Package: Bispecific Antibodies
GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis